Intravenous

Phase 3Small molecule

IIsfahan University of Medical Sciences

Intravenous is one of 80 small molecule programs targeting Parkinsonism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ParkinsonismActive, not recruiting

OverdoseActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

ParkinsonismPhase 2

Active, not recruiting

OverdosePhase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

332 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

39 2

Rituxan

Gemzar

19 4

Gazyva

Roche

Phase 3

18 5

Eloxatin

Teva

Phase 3

17 6

Rayos

RRoxane Laboratories

Phase 3

57 7

Cytoxan

BBaxter Healthcare Corporation

Phase 3

68 8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

29 9

COLUMVI

Cytosar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Not yet recruiting

Parkinsonism

NCT07471230

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma1 trial

A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib

Completed·UUniversity Hospital Southampton NHS Foundation Trust·Phase 3·NCT01324596·1,132 enrolled

Parkinsonism1 trial

Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism

Not yet recruiting·BBiocells Medical·Phase 2·NCT07471230·120 enrolled

Overdose1 trial

Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid Overdose

Completed·IIsfahan University of Medical Sciences·Phase 2·NCT01293058·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Intravenous. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravenous compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravenous. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Isfahan University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIsfahan University of Medical Sciences

Intravenous

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma1 trial

Parkinsonism1 trial

Overdose1 trial

References

Drug Info

Quick Facts

Related News